The FDA (Food and Drug Administration) has approved several drugs targeting RET for the treatment of cancer for example, lenvatinib and sorafenib [10,11,12] for differentiated thyroid cancers, and cabozantinib [13] and vandetanib [10,14] for medullary thyroid carcinomas. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.